High incidence of atrial fibrillation in patients treated with ibrutinib

Objective Atrial fibrillation (AF) is one of the most common side effects of ibrutinib, a drug that has dramatically improved the prognosis of chronic B-cell malignancies such as chronic lymphocytic leukaemia (CLL). The true incidence of ibrutinib-related AF (IRAF) is not well known and its therapeu...

Full description

Bibliographic Details
Published in:Open Heart
Main Authors: Florian Baptiste, Jennifer Cautela, Yan Ancedy, Noémie Resseguier, Thérèse Aurran, Laure Farnault, Marion Escudier, Chloé Ammar, Mélanie Gaubert, Charles Dolladille, Jeremie Barraud, Michael Peyrol, Ariel Cohen, Franck Paganelli, Joachim Alexandre, Stephane Ederhy, Franck Thuny
Format: Article
Language:English
Published: BMJ Publishing Group 2019-05-01
Online Access:https://openheart.bmj.com/content/6/1/e001049.full

Internet

https://openheart.bmj.com/content/6/1/e001049.full

Similar Items